Elisabeth Sandoval Little
CIK 1632295 · CCO & EVP, Corporate Strategy · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$408.1K
Companies
7
Total Filings
32
Lifetime Open-Market Net
-$6.51M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRCT | Director | 15,876 | $25.70 | $408.1K | $0 | 6 | 2026-06-10 |
| VYNE | Director | — | $0.65 | — | $0 | 6 | 2025-12-15 |
| Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Director | — | $1.10 | — | $0 | 4 | 2023-06-08 |
| Intersect ENT, Inc. (XENT) Delisted | Director | — | $28.24 | — | $0 | 2 | 2022-05-16 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Director | — | — | — | $0 | 4 | 2020-08-05 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | CCO & EVP, Corporate Strategy | — | — | — | $0 | 4 | 2018-02-21 |
| KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Chief Commerical Officer | 0 | — | — | -$6.51M | 6 | 2015-10-02 |
Recent Filings · Page 2 of 4
32 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-09 | PRCT | Grant (A) | +2,001 | $75.0K | EDGAR |
| 2022-06-07 | Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-16 | Intersect ENT, Inc. (XENT) Delisted | U | — | $0 | EDGAR |
| 2021-10-25 | PRCT | Grant (A) | +4,935 | $199.7K | EDGAR |
| 2021-07-20 | VYNE | Grant (A) | — | $0 | EDGAR |
| 2021-04-07 | Intersect ENT, Inc. (XENT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-12-07 | Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-08-05 | VYNE Therapeutics Inc. (MNLO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-16 | Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-03-23 | VYNE Therapeutics Inc. (MNLO) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.